- Hindi news
- Bharat Biotech Covaxin Vaccine Latest Clinical Trials Results | Bharat Biotech Phase 3 Clinical Trials for Covaxin
Troubled with Ads? Install Dainik NewsBust India app for news without ads
2 minutes ago
- Copy link
Bharat Biotech has given a lot of good news about indigenous vaccine Kovaxin. The company on Wednesday released the interim results of phase-3 clinical trials of the vaccine. This vaccine has been proven to be effective up to 81%. The government had given emergency approval to the vaccine in the first week of January. This decision of the government was on the target of experts as they were against Emergency Approval without seeing the Phase-3 results.
Hyderabad-based company Bharat Biotech has developed this vaccine in collaboration with the Indian Council of Medical Research (ICMR). The special thing is that many ministers, including Prime Minister Narendra Modi, have recently taken dosages of Kovacsin.
Covaxin also works against variants of Corona
Bharat Krishna Biotech Chairman and Managing Director Dr. Krishna Alla says that this is a day of great achievement for us. In the three phases of clinical trials, we have used our vaccine on 27 thousand volunteers. With the results of Phase-3 clinical trials, it has been proven that covaxin is effective against coronaviruses. This vaccine is also effective against other variants of coronavirus that are rapidly emerging.
43 volunteers get corona infection
There were 25,800 volunteers in Kovaxin’s Phase-3 clinical trials. This is by far the largest figure in the clinical trial of the Corona vaccine in India. Of these, 2,433 people were over 60 years of age, while 4,500 volunteers were suffering from serious illnesses. Of these, 43 volunteers have been found to be infected with coronavirus. 36 belonged to the placebo group, while only 7 belonged to the vaccine group. On this basis, the efficacy of the vaccine has been 80.6%.
Covaxin’s vestage also reduced
Covaxin or BBV152 is a Whole Viron inactivated SARS-CoV-2 vaccine. It is made from Vero Sales. It is stable at 2 to 8 ° C and is being transported in ready-to-use liquid formation. It is suitable for existing vaccine supply chain channels. BBV152 is also accompanied by a 28-day open cell policy, which reduces the vaccine waste by 10-30%.